- Home
- HHS vs VYNE Comparison
HHS vs VYNE Comparison
Compare HHS & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HHS | VYNE |
|---|---|---|
| Founded | 1923 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.2M | 20.4M |
| IPO Year | 1994 | 2017 |
Fundamental Metrics
Financial Performance| Metric | HHS | VYNE |
|---|---|---|
| Price | $2.83 | $0.61 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 17.0K | ★ 138.7K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 97.35 | 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $159,570,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.22 | $0.29 |
| 52 Week High | $5.39 | $1.98 |
Technical Indicators
Market Signals| Indicator | HHS | VYNE |
|---|---|---|
| Relative Strength Index (RSI) | 53.23 | 52.85 |
| Support Level | $2.28 | $0.56 |
| Resistance Level | $2.98 | $0.75 |
| Average True Range (ATR) | 0.19 | 0.02 |
| MACD | 0.06 | 0.00 |
| Stochastic Oscillator | 51.46 | 68.54 |
Price Performance
Historical ComparisonAbout HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company is also in the pre-clinical stages of research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in human. Its products include AMZEEQ, ZILXI, and FCD105.